MedTrace Logo

Gene Expression Profiles in CML Non-responders

NCT04219111 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2020-01-06

No results posted yet for this study

Summary

Chronic myeloid leukaemia (CML) is a haematological malignancy primarily driven by the fusion oncogene BCR-ABL1, resulting in a constitutively expressed tyrosine kinase. CML is treated very effectively by the tyrosine kinase inhibitors (TKIs) resulting in almost undetectable levels of disease. However, some patients show resistance to first line treatment, requiring second and third generation TKIs. Such resistance is due to the presence of tyrosine kinase domain (TKD) mutations, however TKDs do not appear to be present in all patients who do not respond to treatment.

The aim of this project is to utilise gene expression arrays to identify transcriptomic profiles associated with resistance to TKIs in the absence of a demonstrable TKD mutation. The presence of such profiles may allow for a more targeted approach to treatment, if non-responders can be identified earlier in the disease management pathway. Being able to predict those that will not respond to first line treatment will allow for better stratification of patients.

Conditions

  • Gene Expression Profiles in CML Non-responders

Interventions

GENETIC

Clariom

Clariom S Assay

Sponsors & Collaborators

  • Sheffield Children's NHS Foundation Trust

    lead OTHER

Eligibility

Min Age
17 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-01
Primary Completion
2018-05-04
Completion
2018-05-04

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04219111 on ClinicalTrials.gov